Health

NeuroPace Announces Distribution Agreement with DIXI Medical USA, Provider of Intracranial Electrodes and Instruments for Neurosurgery

MOUNTAIN VIEW, California., Aug 11, 2022 (GLOBE NEWSLETTER) — NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people with epilepsy, today announced that the company has entered into a commercialization agreement with DIXI Medical® United States (“DIX”). NeuroPace will be the exclusive U.S distributor of DIXI’s product line effectively October 1, 2022.

Under the terms of the agreement, NeuroPace will have the exclusive rights to promote and sell Stereo Electroencephalography (SEEG) electrodes in the U.S DIXI will continue to support U.S physicians, as well as education and outreach activities to inform patients and caregivers about available treatment options for refractory epilepsy. For these support services, DIXI will receive an upfront payment, along with two additional payments in 2023 and 2024. SEEG electrodes are used in the epilepsy monitoring units of comprehensive epilepsy centers to determine the origin of seizures. Physicians use this information to target interventional treatments at the source of the seizure, including with the NeuroPace RNS System®.

Read:CNA Leadership Summit: Mental Health @ Work – S1: Singlife with Aviva supports Mental Wellness @ Work

“Epilepsy centers in the U.S are increasingly using SEEG as a minimally invasive approach to determine appropriate treatment options for epilepsy patients, including through the use of the RNS system,” said Mike FavetCEO of NeuroPace. “This synergistic collaboration leverages the existing NeuroPace field organization, which already appeals to the same customers, and supports our goal to intervene earlier in the diagnostics and therapy selection process.”

“As SEEG becomes more and more popular among U.S epileptologists and neurosurgeons, we had to increase our reach. We are pleased to entrust DIXI electrodes in the: U.S to the strong and competent team of NeuroPace. The untapped potential of interventional treatments for epilepsy is so great that it deserves the combination of our companies’ energy and creativity.” Frederic Koehn, president of DIXI Medical. “As a specialist in this market for over 40 years, DIXI shares a commitment with NeuroPace to provide innovative solutions for healthcare providers to better manage epilepsy care.”

Read:Why 1 VC is Fed Up with the Concept of Digital Health Unicorns

About epilepsy
One in 26 Americans will develop epilepsy in their lifetime, with about 150,000 new cases of epilepsy each year. Currently, an estimated 3.4 million Americans are living with epilepsy. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures. More people live with epilepsy than autism spectrum disorder, Parkinson’s disease, multiple sclerosis and cerebral palsy – combined.1

About the RNS® System
the RNS® System, a paradigm-shifting treatment for drug-resistant focal epilepsy, is the only brain-responsive neuromodulation system approved by the FDA. Closed-loop technology delivers a personalized, data-driven treatment targeting the seizure source by continuously monitoring brain activity, recognizing a patient’s unique seizure pattern, and responding in real time with imperceptible stimulation to prevent seizures. By recording ongoing EEG data, the RNS system provides physicians with a unique “window to the brain,” allowing them to monitor their patients remotely, gain insights based on brain activity, and use that information to optimize patient care. Long-term clinical studies show that the RNS system provides significant reductions in seizure frequency and lasting improvements in quality of life and cognition without stimulation-related side effects. The RNS System is available at most comprehensive epilepsy centers in the United States and is well covered by insurance. It is currently approved in the United States for patients 18 years of age and older with drug-resistant focal epilepsy. See important safety information at www.neuropace.com/safety/.

Read:Man charged with murdering nurse practitioner also attacked Duke medical worker in 2019, court documents show

About NeuroPace, Inc.
Located in Mountain View, California., NeuroPace is a medical device company focused on transforming the lives of people with epilepsy by reducing or eliminating the occurrence of debilitating seizures. The new and differentiated RNS system is the first and only commercially available brain-responsive platform that delivers personalized, real-time treatment at the source of the seizure. This platform can provide a better standard of care for patients suffering from drug-resistant epilepsy and has the potential to provide a more personalized solution and better outcomes to the large population of patients suffering from other brain disorders.

About DIXI Medical
Forty years ago, French and Italian neurosurgeons pioneered intracerebral diagnostics for epilepsy called stereoelectroencephalography (SEEG). They approached DIXI, a French company based in Besançon, to develop the first SEEG electrodes. Since then, DIXI has continued to develop this revolutionary diagnostic tool, enabling accurate localization of epileptic zones. DIXI sells its product in more than 40 countries around the world and started commercialization in the US market in 2019.

Forward-Looking Statements
In addition to background and historical information, this press release contains “forward-looking statements” based on NeuroPace’s current expectations, forecasts and beliefs, including NeuroPace’s expectations and beliefs about future growth, commercialization efforts, expected returns, growth plans and revenue expectations, as well as our assumptions underpin these expectations. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including the possibility of delays or failures in connection with implementation, regulatory action, failure to maintain or renew important customer and other business relationships, failure to competitive offerings, the possibility of adverse outcomes and other risks associated with our commercialization efforts or activities. You should not place undue reliance on these statements or the information presented. These and other risks and uncertainties include those described more fully in the section entitled “Risk Factors” and “Management’s Discussion and Analysis of the Financial Condition and Results of Operations” and elsewhere in its public filings with the US Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K for the year ended December 31, 2021 submitted to the SEC On March 10, 2022 and the Quarterly Report on Form 10-Q to be filed with the SEC On August 11, 2022as well as any reports it may submit to the SEC in the future. Forward-looking statements in this announcement are based on information available to: NeuroPace from the date hereof. NeuroPace assumes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as a representation of NeuroPace’s views as of a date after the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on forward-looking statements when drawing any conclusion or investment decision about securities of NeuroPace.

Media contacts:
Health+Commerce for NeuroPaceShay Smith[email protected]

Contact for investors:
Gilmartin GroupMatt BacsoCFA
[email protected]

_________________________
1Epilepsy Foundation. “Facts About Seizures and Epilepsy.”

Primary logo

Source: NeuroPace, Inc.

2022 GlobeNewswire, Inc., source: Press releases

Previous post
Vince McMahon reportedly shouted derogatory things about Bray Wyatt’s physique, McMahon’s inner circle started rumors about Bray’s “bad attitude” – Wrestling News
Next post
Ralf Rangnick comments on Marcus Rashford transfer as PSG eye move for Man Utd star